The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
7min 32 secs Tony Burt "Listeners have to remember that outside of the UK is only a couple of real global players in premium mixers and we are one of them, and so Asia makes up 60% of the world's population, so you know there is incredible opportunity for us in the Asia Pacific."
Really pleased with today going forward.
There are two groups looking at this. One obsessed on price and the second one looking at the actual business.
The price was pitched at 0.47p on return and what would have happened, be honest! A lot of holders would have sold for peanut profits and be happy they got their money back. The price would then have sat back at around 0.3p and then the same sellers would have then been in and out all day everyday dragging the price. We then go nowhere fast.
At 0.3p those who wanted 0.47p are now in a mire not knowing what to do. Get their money back would be my first guest. Those looking at the growth in the cannabis industry and going forward will no doubt be adding.
I could be reading it wrong but from some of the posts its blatantly clear some like showing their cards.
Widglide
Clearly the market does take the RNS as positive. Your problem is twofold. You are down heavily on this stock and you are mixing too many personal variables into the mix which then muddles up your outcome. You are now not seeing it for the business it is which then put fear into you adding more, and so you sit watching patiently at break even, pondering whether that would be possible and a good time to get out.
No one can stop the early morning buyer of 253k shares who then sells 7 minutes later for a loss or a small £10 profit. Each to their own! The fact that close to 50% is held by solid institutions give confidence that when company changing news does land, our 253k friend will have real problems filling that and making £10 profit.
Widglide, the price could and should be maybe closer to 3p, but while it is down here, some of us can throw spare money at this because the opportunity is there and we are well aware of the risks of any investment. Block out the noise if you can and makes a massive amount of difference. If you don’t then I expect more of the same from you and you will be your own enemy.
CorePath Laboratories
@CorePath
·
21s
Thank you Dr. Allan Syms Exec. Chairman of
@CizzlePlc
for visiting CorePath. Excited to continue partnership to develop & offer a proprietary #earlystage #lungcancer test throughout the USA.
On track to validating/commercializing the test in 2023.
Its only been 15 mins since my last post and it has gone from 1.5% to 18% up. Catching up started.
Agreed Aimtrader we have some catching up, but the difference is Herd V Investors. There are loads who will follow the herd and very few who have the patience to invest. That is reflected here. The buys this morning apart from a few have all in the main being those adding to the current holding, in my opinion. In Vela no idea other than the frequency and speed of trading indicates traders not investors.
CIZ will have its day, very soon. I am trying to put together AS has indicated a trip to the USA in the very week that Conduit have announced a NASDAQ listing. The partnership looks very healthy, so hopefully there will be more to this. I was very impressed by the work they do, but was left confused as to why they sold out their share in CIZ. Not sure about what they have done with the latest tranche in CIZ?
The fact that Taylor Partners Limited has sold down 12m odd shares has given others the chance to add more at these cheap levels. If they have stopped then I expect a correction back upwards
Agreed Jace
End game for me too. No reason to sell. Saving lives is the priority, and if the investment grows from it, so be it.
Good luck mate.
The price is the meantime has reacted very strongly in the positive. Was 1.3-1.6 at the time of the announcement, and now moving to 1.6-1.7p and buys are rolling in.
This part stands out for me:
-- Market launch and preparation for a clinical trial to support NHS and other global healthcare providers
Cizzle Biotechnology Holdings PLC Subscription, Facility & Publication of Prospectus
21/09/2022 11:23am
UK Regulatory (RNS & others)
Cizzle Biotechnology, the UK-based diagnostics developer, is pleased to announce that it has conditionally raised gross proceeds of GBP500,000 by way of the Subscription and secured a further GBP500,000 pursuant to the Facility in order to provide funds to progress the Group's strategy.
Highlights
-- Subscription to raise GBP500,000 through the issue of new Ordinary Shares at 1.5p per share ("Issue Price")
-- A further Facility of GBP500,000 is available to the Company, subject to Admission, to provide further funds, if required, repayable in shares at a fixed price of 1.8p per share
-- The funds raised will be used, inter alia, to provide working capital for the Company's strategy and to continue development of a laboratory-developed test ("LDT") accredited service for the early detection of lung cancer and taking the Company's proprietary CIZ1B biomarker blood test through to UKCA, CE marking and/or FDA 510(k) clearance
Use of proceeds
The proceeds of the Subscription, which are expected to total approximately GBP500,000 (before expenses of GBP40,000 excluding VAT), will be used to provide working capital for the Company and to fund the following:
-- Continued development of the test reagents, manufacture of test reagents, and validation of test configuration on patient samples
-- Development of a LDT certified test in accredited partner laboratories such as CorePath Laboratories, USA
-- Production of a UKCA, CE marked and/or FDA 510(k) cleared product, following successful validation on retrospective clinical sample sets and control cohorts
-- Market launch and preparation for a clinical trial to support NHS and other global healthcare providers
Nevada: Now this would be big. Only said that the other day to someone and glad you highlighted that as well.
Steve
Could you give a breakdown to what type of financing CIZ will need in your opinion?
What price the placing you believe will happen in your opinion later in the year and what the placing would be for?
What makes you think they will need financing?
You are not convinced that not too much money is coming in? Are you able to confirm your own findings?
If the directors were to buy what will that confirm to you? I know what it will confirm to me.
If the directors do not buy, are you aware of the reasons for that?
I am sure at some point you will read, and maybe reply. No rush.
(The above is based on all your previous and current posts on CIZ, over 30 days)
RNS Number : 3098Q
Cizzle Biotechnology Holdings PLC
27 June 2022
27 June 2022
Cizzle Biotechnology Holdings Plc
("Cizzle Biotechnology" or the "Company")
Result of AGM
Cizzle Biotechnology, the UK based diagnostics developer, announces that at the Annual General Meeting ("AGM") of the Company held earlier today, all resolutions were voted on by a poll and were passed.
*******************************************************************************************************
Decent buying coming through so hopefully the rerate is now happening.
Licker thanks for the reply mate. At this moment we really don't know what MM wants or is thinking and the danger is many investment decisions are made on emotional belief. He said one thing and it has been blown up out of proportion and exaggerated. The biggest danger is the herd mentality so obvious on here, and also the dirty mind games others are conveniently attempting to get weak holders to part with their shares. Patience, Patience and more Patience and that is not easy I accept, but in investing is vital. I don't know if MM wants to delist or remain, what we do know is that a couple of others have chanced their hand and been declined, and the stock volatiity due to that has moved from one group of short term holders to others who can read the situation.
I read yesterday "The only way you will die in the roller coaster ride is if you jump off! That applies here.
Yes licker you have missed something obvious. MM and co, are running a business that is trying to find the best solution to provide for the retail market, whether remaining on the market or private. We are just along for the ride, and once someone (not saying you) gets fixated on the shareprice, they either miss the opportunity to add in a growing business, or get desperate (not saying you) to cash in at the first opportunity. whether its £2.50 £3, or whatever. I am a customer of THG and really see the potential of D2C.
Customers are first priority otherwise THG is nothing.
BTW anyone again know why Form 8.5 are still being RNS'ed or am I directing my question to traders only here? (apologies if that is the case, I will try and find another route to my answer).
Commenting, Bill Behnke, Founder of The Behnke Group, said:
"I recently attended ASCO22, a major clinical sciences conference in Chicago, USA, where multiple meetings evidenced considerable interest in Cizzle Biotechnology's entry into the USA. Cizzle Biotechnology fits perfectly with the Behnke Group's mission to achieve better outcomes, lower costs and improve the health and safety of patients. We are excited to add Cizzle Biotechnology to our portfolio of game changing businesses."
REPEAT: "where multiple meetings evidenced considerable interest in Cizzle Biotechnology's entry into the USA. "
Looks like they have been busy in the USA. I understand there is a concern of about funding, but the forthcoming £1m from SGSC should be noted, plus I am sure there would be plenty of other suitors willing to fund the next stage without having to come to market?
Director buys now would mean currently nothing on the agenda and no close period. If no buys it should be seen as a positive, as there may be something still being worked in the background, and they don't want to be caught insider trading.
Secondly can anyone explain why we are still getting Form 8.5 RNS this morning? Even though both potential bids have been squashed. Is there still period of disclosure even after the confirmation from the two parties of pursuing? Or is there something relevant to Rule 2.8?
CIZ is now showing a lot of confidence in the price. Holding very well and threatening to go back above 2p at the least. As hard it has been for some, the price is a complete detachment from what is actually going on with the company. You can either moan at the drop or use it to add through price weakness, if reserves allow.
Never been more confident.
Absolutely agree given its whey protein concentrate (milk) 100% with none of the harmful additives others put in. 21g protein per 25g serving. As in a previous post I know a few who buy these in bulk and they are very satisfied. I can only see more sales down the line. Crazy as I am trying help someone gain weight, and made a deal I will supply a whole year's worth of MyProtein if this hits £2.50+ to them. As I have tried this myself I rate it better than most out there. Others are entitled to their opinions.